stoxline Quote Chart Rank Option Currency Glossary
  
Reata Pharmaceuticals, Inc. (RETA)
172.36  0.04 (0.02%)    09-25 16:00
Open: 172.34
High: 172.46
Volume: 1,909,215
  
Pre. Close: 172.32
Low: 172.32
Market Cap: 6,566(M)
Technical analysis
2023-10-20 4:26:05 PM
Short term     
Mid term     
Targets 6-month :  201.43 1-year :  235.27
Resists First :  172.46 Second :  201.43
Pivot price 171.64
Supports First :  170.04 Second :  168.55
MAs MA(5) :  172.28 MA(20) :  171.01
MA(100) :  127.81 MA(250) :  83.23
MACD MACD :  3.4 Signal :  4.4
%K %D K(14,3) :  97.6 D(3) :  97.5
RSI RSI(14): 84.6
52-week High :  172.46 Low :  21.82
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RETA ] has closed below upper band by 29.6%. Bollinger Bands are 86.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 172.56 - 173.47 173.47 - 174.24
Low: 170.15 - 171.21 171.21 - 172.11
Close: 170.64 - 172.42 172.42 - 173.93
Company Description

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Headline News

Mon, 25 Sep 2023
Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio? - Yahoo Finance

Wed, 13 Sep 2023
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future - Yahoo Finance

Fri, 28 Jul 2023
Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B - Seeking Alpha

Fri, 28 Jul 2023
Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs - Investopedia

Fri, 28 Jul 2023
Biogen (BIIB) Weighs Takeover of Drugmaker Reata (RETA) - Bloomberg

Fri, 28 Jul 2023
Intel, Reata Pharma and Roku rally, and other movers - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -128 (M)
Shares Float 0 (M)
Held by Insiders 3.359e+007 (%)
Held by Institutions 2.979e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6763e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.6
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 455.1 %
Return on Equity (ttm) -37.7 %
Qtrly Rev. Growth 2.348e+007 %
Gross Profit (p.s.) -54.66
Sales Per Share 0
EBITDA (p.s.) -1.1641e+008
Qtrly Earnings Growth -3.4054e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -66.3
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 2.39e+006
Forward Dividend 4.2e+006
Dividend Yield 1386630%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android